BPTSY (Biophytis) Accumulated Depreciation: $0.00 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BPTSY Biophytis SA BPTSY
18 GF Score
Price $0.25
! 5 Warning Signs
View Full Analysis

What is Biophytis Accumulated Depreciation?

Biophytis BPTSY 18 Accumulated Depreciation is $0.00 Mil as of Jun. 2025. GuruFocus rates BPTSY with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Biophytis's quarterly accumulated depreciation increased from Jun. 2024 ($0.00 Mil) to Dec. 2024 ($-0.79 Mil) but then stayed the same from Dec. 2024 ($-0.79 Mil) to Jun. 2025 ($0.00 Mil).

Biophytis's annual accumulated depreciation declined from Dec. 2022 ($-1.02 Mil) to Dec. 2023 ($-0.73 Mil) but then increased from Dec. 2023 ($-0.73 Mil) to Dec. 2024 ($-0.79 Mil).

Biophytis Accumulated Depreciation Related Terms

Biophytis Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Biophytis's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biophytis Accumulated Depreciation Chart

Biophytis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.66 -0.76 -1.02 -0.73 -0.79

Biophytis Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.48 -0.73 0.00 -0.79 0.00
BPTSY
18GF Score
Biophytis SA BPTSY
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biophytis Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $0.00 Mil mean?
Biophytis (BPTSY) has a Accumulated Depreciation of $0.00 Mil as of Jun. 2025. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Biophytis and its competitors.
Is Biophytis' Accumulated Depreciation too high?
Biophytis' current Accumulated Depreciation is $0.00 Mil. Overall, Biophytis has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biophytis' Accumulated Depreciation compare to VRTX and REGN?
Biophytis' Accumulated Depreciation of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Biophytis and its competitors. Biophytis's current Accumulated Depreciation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biophytis stock overvalued right now?
Biophytis (BPTSY) has a current Accumulated Depreciation of $0.00 Mil. The current Accumulated Depreciation is $0.00 Mil. Biophytis' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Biophytis (BPTSY), the current Accumulated Depreciation is $0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biophytis Business Description

Address BC 9, Batiment A 4eme etage, 4 Place Jussieu, Sorbonne University, Paris, FRA, 75005
Biophytis SA is a France-based clinical-stage biotechnology company engaged in the development of drug candidates for the treatment of age-related and respiratory diseases. The company focuses on therapies that target degenerative processes associated with aging and improve functional outcomes. Its drug candidate, BIO101, is an orally administered small molecule under development for neuromuscular and respiratory indications, including sarcopenia, Duchenne muscular dystrophy (DMD), and respiratory failure.
18GF Score

Get the complete analysis for BPTSY

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price